KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and hypoglycaemia outcomes of once-weekly insulin icodec versus once-daily basal insulin comparators across baseline HbA1c, BMI and duration of type 2 diabetes subgroups: A post hoc analysis of ONWARDS 1-5.

Alice Y Y Cheng, Gayathri Anil, Luis Canani, Siri Vinther, Ni Wang, Chantal Mathieu

Diabetes Obes Metab 28(3) 1778-1790

PMID41387317
PMCIDPMC12890738
DOI10.1111/dom.70358
发表日期2025-12-12
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图。
摘要

摘要

AIMS: This post hoc analysis assessed efficacy and hypoglycaemia outcomes of once-weekly insulin icodec (icodec) versus once-daily (OD) basal insulin comparators across different baseline glycated haemoglobin (HbA1c), body mass index (BMI) and type 2 diabetes (T2D) duration subgroups using data from five phase 3a trials of icodec in adults with T2D. MATERIALS AND METHODS: Treatment outcomes were assessed, by trial, in insulin-naive (ONWARDS 1, 3 and 5) and insulin-experienced (ONWARDS 2 and 4) adults across baseline HbA1c (≤8%, >8% to ≤9% and >9%), baseline BMI (<25 kg/m2, ≥25 to <30 kg/m2, ≥30 to <35 kg/m2 and ≥ 35 kg/m2) and baseline T2D duration (<5 years, ≥5 to <10 years, ≥10 to <15 years, ≥15 years) subgroups. The primary outcome was change in HbA1c from baseline to planned end of treatment. The achievement of HbA1c <7% (<53 mmol/mol) without clinically significant or severe hypoglycaemia and the rate of hypoglycaemic episodes were also assessed. RESULTS: Across trials, the estimated treatment differences for change in HbA1c and odds ratios for achievement of HbA1c <7% without clinically significant or severe hypoglycaemia between icodec and OD basal insulin comparators were overall consistent across baseline HbA1c, BMI and T2D duration subgroups; no statistically significant treatment by subgroup interactions were seen. Hypoglycaemia rates were numerically low for both treatment arms and consistent across subgroups in ONWARDS 1-3 and 5. CONCLUSIONS: The efficacy and hypoglycaemia profile of icodec versus OD basal insulin comparators was overall consistent across trial populations irrespective of baseline HbA1c, BMI or T2D duration.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Estimated treatment difference in change in HbA1c (%‐points) from baseline to planned EOT by baseline (A) HbA1c, (B) BMI and (C) T2D duration. Planned EOT: ONWARDS 1, week 78; ONWARDS 2–4, week 26; ONWARDS 5, week 52. † The p value is for the test of no treatment interaction by subgroup. Modelled using an ANCOVA model with treatment, region, subgroup, treatment by subgroup interaction and, if applicable, additional relevant factors as fixed factors, and baseline response as covariate. Missing data were imputed using multiple imputation. ‡ In ONWARDS 5, icodec titration was guided by a dosing guide app; OD basal insulin comparator doses were titrated at the investigators' discretion as per standard clinical practice. § In ONWARDS 5, participants in the OD basal insulin comparator arm received OD degludec, glargine U100 or glargine U300 at the investigators' discretion. ANCOVA, analysis of covariance; aspart, insulin aspart; BMI, body mass index; CI, confidence interval; degludec, insulin degludec; EOT, end of treatment; ETD, estimated treatment difference; glargine U100, insulin glargine U100; glargine U300, insulin glargine U300; HbA1c, glycated haemoglobin; icodec, insulin icodec; OD, once‐daily; T2D, type 2 diabetes.
非 KM Figure
FIGURE 2FIGURE 2 Estimated odds ratio for the achievement of HbA1c < 7% at planned EOT without clinically significant or severe hypoglycaemia in the previous 12 weeks by baseline (A) HbA1c, (B) BMI and (C) T2D duration. Clinically significant hypoglycaemia: Blood glucose of < 54 mg/dL ( < 3.0 mmol/L), confirmed by blood glucose meter. Severe hypoglycaemia: Hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. † The p value for treatment interaction by subgroup was calculated using a logistic regression model (logit link) with treatment, region, subgroup, treatment by subgroup interaction and, if applicable, additional relevant factors as fixed factors, and the baseline HbA1c, baseline BMI or T2D duration value covariate. Missing data were imputed using multiple imputation. ‡ In ONWARDS 5, icodec titration was guided by a dosing guide app; OD basal insulin comparator doses were titrated at the investigators' discretion as per standard clinical practice. § In ONWARDS 5, participants in the OD basal insulin comparator arm received OD degludec, glargine U100 or glargine U300 at the investigators' discretion. Aspart, insulin aspart; BMI, body mass index; CI, confidence interval; degludec, insulin degludec; EOR, estimated odds ratio; EOT, end of treatment; glargine U100, insulin glargine U100; glargine U300, insulin glargine U300; HbA1c, glycated haemoglobin; icodec, insulin icodec; OD, once‐daily; T2D, type 2 diabetes.
非 KM Figure